Streetbeat News

Stock Prices

SWAV

ShockWave Medical (NASDAQ:SWAV) has received various analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average price target is $275.0, compared to the current price of $200.71, implying an upside. However, this average represents a 11.77% decrease from the previous average price target of $311.67.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

BIIB

An industry comparison of Biogen (NASDAQ:BIIB) and its primary competitors in the Biotechnology industry reveals that Biogen's low PE, PB, and PS ratios suggest that the company's stock is undervalued. However, Biogen's low ROE, EBITDA, gross profit, and high revenue growth may indicate challenges in generating profits and managing expenses.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

EXLS

ExlService Holdings (NASDAQ:EXLS) has received various analyst ratings in the last quarter, with 1 bullish, 4 somewhat bullish, and 3 indifferent. The average price target is $107.62, a significant increase from the current price of $29.47. However, this average has decreased by 21.96% from the previous average price target of $137.90.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

ARMK

Over the past 3 months, 14 analysts have published their opinion on Aramark (NYSE:ARMK) stock. The average price target is $38.46, implying an upside from the current price of $25.35. This represents a 11.57% decrease from the previous average price target of $43.49.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

AZN

A comprehensive industry comparison of AstraZeneca (NASDAQ:AZN) and its primary competitors in the Pharmaceuticals industry reveals that AstraZeneca's P/E ratio is higher than the industry average, suggesting a premium valuation. However, its P/B and P/S ratios are below the industry average, indicating potential undervaluation. The company's ROE, EBITDA, and gross profit are lower than the industry average, suggesting potential inefficiencies and financial challenges. However, AstraZeneca's revenue growth outperforms the industry average.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

SNOW

Snowflake's (NYSE:SNOW) short percent of float has fallen 15.61% since its last report, with 9.29 million shares sold short, which is 2.92% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards Snowflake. Compared to its peers, Snowflake has less short interest as a percentage of float, with an average of 5.55%.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

PKX

POSCO Holdings's (NYSE:PKX) short percent of float has fallen 4.35% since its last report, indicating a decrease in bearish sentiment towards the stock. The company has 1.34 million shares sold short, which is 0.44% of all regular shares available for trading. Compared to its peers, POSCO has less short interest.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

AVGO

Broadcom (NASDAQ:AVGO) is compared with its competitors in the Semiconductors & Semiconductor Equipment industry. The company's P/E ratio of 27.17 is below the industry average, suggesting undervaluation. However, its P/B ratio of 16.51 and P/S ratio of 10.41 are above the industry average, indicating potential overvaluation. Broadcom's ROE of 14.98% is higher than the industry average, suggesting efficient use of equity. However, its EBITDA, gross profit, and revenue growth are lower than the industry average, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

AMGN

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years, producing an average annual return of 12.0%. If an investor had bought $100 of AMGN stock 15 years ago, it would be worth $537.15 today.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

MLTX

MoonLake (NASDAQ:MLTX) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $75.8, a significant increase from the previous average of $51.00.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm